China News Service, February 1st. According to Kyodo News, Japan’s Ministry of Health, Labour and Welfare has recently decided to speed up the development of Japan’s domestically-produced new crown vaccine by subsidizing costs when domestic companies implement large-scale clinical trials.
On January 7, local time, in Tokyo, Japan, people traveled wearing masks.
According to reports, the Japanese-made vaccine has ended its initial clinical trials with a small number of people and has gradually entered the next stage.
In the final stage, tens of thousands of test subjects must be divided into two groups who received real vaccines and placebos, and the number of patients was compared to confirm the effectiveness.
However, there is a problem in Japan that it is difficult to collect and analyze the necessary number of patients with the disease alone. It can be implemented if participants can be recruited overseas. However, because of the huge cost and some companies hesitate to move forward, the government has decided to support the cost.
The target of support is assumed to be companies that have subsidized the cost of improving the production system. If large-scale clinical trials are carried out, the costs of commissioning specialized companies and vaccine transportation costs will be subsidized.
According to previous reports, Japan has signed an agreement or reached an agreement with three European and American pharmaceutical companies including Pfizer Inc. to order 310 million doses of the new crown vaccine, which is scheduled to start vaccination in late February.
Medical staff will be vaccinated first, followed by those over 65 and those with underlying diseases.
The Japanese central government is responsible for vaccine supply, and the local government is responsible for vaccination.